EAM
ALXN

EULAV Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

EULAV Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-148,000
Closed -$23.1M – 244
2020
Q4 		$23.1M Sell
148,000
-74,000
-33% -$9.51M 0.6% 58
2020
Q3 		$25.4M Buy
222,000
+82,000
+59% +$8.85M 0.75% 40
2020
Q2 		$15.7M Sell
140,000
-37,000
-21% -$3.93M 0.51% 65
2020
Q1 		$15.9M Sell
177,000
-65,200
-27% -$6.4M 0.64% 54
2019
Q4 		$26.2M Sell
242,200
-30,000
-11% -$3.21M 0.9% 30
2019
Q3 		$26.7M Buy
272,200
+10,000
+4% +$1.13M 0.98% 25
2019
Q2 		$34.3M Buy
262,200
+5,000
+2% +$644K 1.29% 14
2019
Q1 		$34.8M Sell
257,200
-90,800
-26% -$11.3M 1.43% 12
2018
Q4 		$33.9M Buy
348,000
+38,000
+12% +$4.49M 1.69% 5
2018
Q3 		$43.1M Sell
310,000
-77,000
-20% -$9.66M 1.85% 3
2018
Q2 		$48M Buy
387,000
+15,000
+4% +$1.75M 2.21% 1
2018
Q1 		$41.5M Sell
372,000
-33,000
-8% -$3.94M 1.98% 3
2017
Q4 		$48.4M Buy
405,000
+18,000
+5% +$2.19M 2.29% 1
2017
Q3 		$54.3M Hold
387,000
– – 2.56% 1
2017
Q2 		$47.1M Buy
387,000
+156,000
+68% +$18.2M 2.31% 1
2017
Q1 		$28M Buy
231,000
+10,000
+5% +$1.29M 1.43% 7
2016
Q4 		$27M Sell
221,000
-5,000
-2% -$612K 1.46% 5
2016
Q3 		$27.7M Buy
226,000
+32,000
+16% +$4.12M 1.47% 3
2016
Q2 		$22.7M Buy
194,000
+83,000
+75% +$11.8M 1.24% 6
2016
Q1 		$15.5M Buy
111,000
+34,000
+44% +$4.99M 0.86% 31
2015
Q4 		$14.7M Hold
77,000
– – 0.8% 35
2015
Q3 		$12M Sell
77,000
-6,000
-7% -$1.09M 0.68% 46
2015
Q2 		$15M Hold
83,000
– – 0.79% 28
2015
Q1 		$14.4M Hold
83,000
– – 0.74% 28
2014
Q4 		$15.4M Hold
83,000
– – 0.83% 17
2014
Q3 		$13.8M Sell
83,000
-11,600
-12% -$1.9M 0.75% 22
2014
Q2 		$14.8M Hold
94,600
– – 0.79% 21
2014
Q1 		$14.4M Sell
94,600
-6,000
-6% -$954K 0.78% 19
2013
Q4 		$13.4M Hold
100,600
– – 0.73% 28
2013
Q3 		$11.7M Sell
100,600
-24,000
-19% -$2.63M 0.68% 34
2013
Q2 		$11.5M Buy
+124,600
New +$12M 0.7% 27

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EULAV Asset Management's ALXN Position: Q1 2021 in Review

EULAV Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 148,000 shares — an estimated $23.1M sold.

EULAV Asset Management first reported a position in ALXN in Q2 2013 and held it in 31 quarters. The position peaked at $54.3M in Q3 2017. 753 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • EULAV Asset Management reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • EULAV Asset Management sold 148,000 Alexion Pharmaceuticals shares in Q1 2021, an estimated $23.1M.
  • EULAV Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 31 quarters.
  • EULAV Asset Management's Alexion Pharmaceuticals position peaked at $54.3M in Q3 2017.
  • 753 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on EULAV Asset Management's 13F filing for Q1 2021, filed 30 Apr 2021.